Chosa Oncology AB

Equities

CHOSA

SE0007784319

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 04:30:00 01/02/2024 am IST			5-day change	1st Jan Change
0.53 ^SEK	+51.43%		-.--%	-6.03%

30/04	Chosa Oncology AB Announces Resignation of Lars Hedbys as Chairman	CI
28/03	Chosa Oncology Names CFO, Chief Commercial Officer	MT

BioStock: RhoVac gives update on phase IIb results and presents action plan

July 04, 2022 at 11:33 am IST

Just over a month ago, Lundbased Rhovac reported topline results from the phase IIb study with the drug candidate onilcamotide, where unfortunately they did not see the hoped-for effect. After taking a closer look at the results, the company has given another update and presented some possible ways forward. BioStock contacted RhoVac's CEO Anders Månsson to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/07/rhovac-gives-update-on-phase-iib-results-and-presents-action-plan/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/rhovac/r/biostock--rhovac-gives-update-on-phase-iib-results-and-presents-action-plan,c3595410

Latest news about Chosa Oncology AB

Chosa Oncology AB Announces Resignation of Lars Hedbys as Chairman	30/04	CI
Chosa Oncology Names CFO, Chief Commercial Officer	28/03	MT
CHOSA Oncology AB Announces Chief Financial Officer Changes	28/03	CI
CHOSA Oncology Appoints Claus Frisenberg Pedersen as Chief Commercial Officer	28/03	CI
Chosa Oncology AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02	CI
Chosa Oncology AB Postpones Publication of Interim Report for the Second Quarter of 2023	27/23/27	CI
CHOSA Oncology AB Publishes Results from Clinical Phase 2 Trial of Liposomal Formulation in Breast Cancer, Using Predictive Marker for Cisplatin	03/23/03	CI
Chosa Oncology AB Announces Board Changes	26/23/26	CI
CHOSA Oncology AB Presents Clinical Phase 2 Results of LiPlaCis and its Drug Response Predictor Test at ASCO 2023	26/23/26	CI
RhoVac AB will Change its Name to CHOSA Oncology AB	15/23/15	CI
RhoVac AB has Changed its Name to CHOSA Oncology AB	10/23/10	CI
Rhovac AB Announces CEO Changes	18/23/18	CI
RhoVac AB Announces Board Changes	18/23/18	CI
Chosa ApS completed the acquisition of RhoVac AB from M2 Asset Management AB and others in a reverse merger transaction.	18/23/18	CI
Chosa ApS entered into an agreement to acquire RhoVac AB from M2 Asset Management AB and others in a reverse merger transaction for SEK 30.4 million.	05/22/05	CI
RhoVac AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
RhoVac AB Announces Resignation of Anders Ljungqvist as Board Member	18/22/18	CI
RhoVac AB Appoints Lars Hedbys as Acting CEO, Starting from September 1, 2022	26/22/26	CI
RhoVac AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	26/22/26	CI
Rhovac AB Announces Resignation of Anders Månsson as CEO	15/22/15	CI
RhoVac AB's Phase IIb Study in Prostate Cancer , BRaVac, Failed to Meet Its Primary Endpoint	30/22/30	CI
Pre-Clinical Findings Support the Potential Use of RhoVac AB's Drug Candidate, Onilcamotide, Across Several Cancers	18/22/18	CI
RhoVac AB Reports Earnings Results for the First Quarter Ended March 31, 2022	05/22/05	CI
RhoVac AB Announces Scientific Publication Supports its Cancer Treatment Method	01/22/01	CI
RhoVac AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	12/22/12	CI

Chart Chosa Oncology AB

Duration

Period

More charts

Company Profile

Chosa Oncology AB, formerly RhoVac AB, is a Sweden-based biotechnology company. The Company specializes on research and development of immunotherapeutic drugs. The Company's business focus is found in the development of vaccines for the treatment of metastatic cancer. Immunotherapy treatment is an important part of the operation where the body's own immune system is used to fight and eliminate cancer cells. The Company's drug candidate is used in combination with surgery or radiotherapy. Its products are iCIP, which is combines the identification of patients that will benefit from cisplatin treatment with the ability to treat them with higher efficacy and less toxicity; LiPlaCis is a liposomal formulation of cisplatin enabling direct delivery of this known agent to tumor sites; and DRP is a multigene mRNA-based Drug-specific Response Predictor built upon a deep systems biology analysis of all transcriptional (RNA) changes in tumor cells in response to a broad range of drug types.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CHOSA ONCOLOGY AB	-6.03%	35.44L
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	12TCr
REGENERON PHARMACEUTICALS, INC.	+10.80%	11TCr
BIONTECH SE	-10.84%	2.34TCr
ARGENX SE	-1.69%	2.21TCr
GENMAB A/S	-10.23%	1.83TCr
WUXI APPTEC CO., LTD.	-41.92%	1.66TCr
BEIGENE, LTD.	-15.11%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+6.62%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+17.53%	1.17TCr

Bio Therapeutic Drugs